PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDeferasirox
Exjade(deferasirox)
Deferasirox, Exjade, Jadenu (deferasirox) is a small molecule pharmaceutical. Deferasirox was first approved as Exjade on 2005-11-02. It is used to treat iron overload in the USA. It has been approved in Europe to treat beta-thalassemia and iron overload.
Download report
Favorite
Novartis Pharmaceuticals
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hemic and lymphatic diseasesD006425
hereditary congenital and neonatal diseases and abnormalitiesD009358
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Deferasirox, Exjade, Jadenu (discontinued: Deferasirox)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Deferasirox
Tradename
Company
Number
Date
Products
EXJADENovartisN-021882 RX2005-11-02
3 products, RLD, RS
JADENU SPRINKLENovartisN-207968 RX2017-05-18
3 products, RLD, RS
JADENUNovartisN-206910 RX2015-03-30
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
deferasiroxANDA2024-09-26
deferasirox oralANDA2022-04-12
deferasirox oral granulesANDA2023-12-28
deferasoroxANDA2022-05-20
exjadeNew Drug Application2024-07-22
jadenuNew Drug Application2024-07-18
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
iron overload—D019190—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Deferasirox, Jadenu, Novartis Pharms Corp
92832092034-11-21DS, DP
ATC Codes
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AC: Iron chelating agents
— V03AC03: Deferasirox
HCPCS
No data
Clinical
Clinical Trials
105 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Iron overloadD019190——32610131057
ThalassemiaD013789EFO_1001996D56317781040
Beta-thalassemiaD017086Orphanet_848D56.121155727
Myelodysplastic syndromesD009190—D4611517226
PreleukemiaD011289——11117222
SyndromeD013577———917219
HemosiderosisD006486——1844116
HemochromatosisD006432EFO_1000642E83.111744115
AnemiaD000740HP_0001903D64.9—614213
Sickle cell anemiaD000755EFO_0000697D57—531—8
Show 3 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Primary myelofibrosisD055728—D47.4—21——3
Porphyria cutanea tardaD017119—E80.1—11——2
Erythropoietic porphyriaD017092—E80.0—11——2
PorphyriasD011164EFO_0000665——11——2
Hepatic porphyriasD017094———11——2
Oxidative stressD018384EFO_1001905——11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C9514——16
Myeloid leukemia acuteD015470—C92.023——16
Myeloid leukemiaD007951—C9212——14
Precursor cell lymphoblastic leukemia-lymphomaD054198——12———3
Lymphoid leukemiaD007945—C9112———3
Multiple myelomaD009101—C90.0—3———3
LymphomaD008223—C85.9—3———3
Plasma cell neoplasmsD054219———3———3
MycosesD009181—B35-B49—2———2
RecurrenceD012008———2———2
Show 63 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———2————2
Liver diseasesD008107HP_0002910K70-K771————1
Hepatic insufficiencyD048550——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I10————11
Pulmonary hypertensionD006976EFO_0001361I27.20————11
HemolysisD006461——————11
NeoplasmsD009369—C80————11
Mouth neoplasmsD009062EFO_0003868C06.9————11
EndotoxemiaD019446——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDeferasirox
INNdeferasirox
Description
Deferasirox is a member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patients receiving long-term blood transfusions. It has a role as an iron chelator. It is a member of triazoles, a monocarboxylic acid, a member of benzoic acids and a member of phenols. It is functionally related to a 2,2'-(1-phenyl-1H-1,2,4-triazole-3,5-diyl)diphenol.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1
Identifiers
PDB—
CAS-ID201530-41-8
RxCUI—
ChEMBL IDCHEMBL550348
ChEBI ID49005
PubChem CID214348
DrugBankDB01609
UNII IDV8G4MOF2V9 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Exjade – Novartis
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 3,852 documents
View more details
Safety
Black-box Warning
Black-box warning for: Deferasirox, Deferasirox oral, Deferasirox oral granules, Deferasorox, Exjade, Jadenu
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
30,734 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use